<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263054</url>
  </required_header>
  <id_info>
    <org_study_id>100-10-0001</org_study_id>
    <nct_id>NCT01263054</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the TransDiscal System Versus Medical Management in Treating Chronic Discogenic Low Back Pain</brief_title>
  <acronym>COLD</acronym>
  <official_title>A Prospective, Randomized, Multi-Center, Open-Label Clinical Trial Comparing Disc Biacuplasty With Medical Management for Discogenic Lumbar Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halyard Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halyard Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this randomized controlled trial is to evaluate the safety and
      efficacy of the TransDiscal System (TDS) in treating discogenic pain of the lumbar spine
      using a modified disc biacuplasty procedure. The primary efficacy measure will be the Visual
      Analog Scale (VAS) at 6 months post treatment/randomization and the TransDiscal System will
      be compared against medical management (standard of care).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intervertebral discs serve as joints between the vertebral bodies, providing both
      structural support and flexibility to the spinal column. Intervertebral discs do not remain
      structurally intact over a lifetime and degenerate as a natural part of aging. Degenerated
      discs do not react to stresses and forces the same as healthy discs. When too much stress is
      applied to a degenerated disc, tears can result. Evidence suggests that when a tear is
      present, sensory nerve endings can grow into the tear and transmit pain.

      The TransDiscal System (TDS) is a medical device that is used in a procedure called Disc
      Biacuplasty and is currently available in the United States and throughout the world. The TDS
      enables the back of the disc to be heated to high enough temperatures to ablate the nerves
      inside that are transmitting pain, while maintaining low enough temperatures to prevent
      damage to surrounding tissues. The TDS uses two electrodes, located at the ends of two thin
      probes, which are placed on both sides of the back of the intervertebral disc by inserting
      them through the skin into the disc using x-ray guidance. Radiofrequency (RF) current flows
      in the disc between the two electrodes, heating the tissue in the disc to the desired
      temperature. The study evaluates a modified heating protocol than what is currently in
      clinical use which should allow for a larger area of the back of the disc to be heated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Average Daily Pain Visual Analog Scale (VAS) Score Between Screening and Follow up.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Visual Analog Scale (NRS) - score range = 0 - 10. &quot;0&quot; corresponds to &quot;no pain&quot; and &quot;10&quot; indicates &quot;worst pain imaginable&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Study Group Subjects With Greater Than 2 Points Decrease or 30% Drop in Average Daily Pain Related Visual Analog Scale (VAS) Score.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Visual Analog Scale (NRS) - score range = 0 - 10. &quot;0&quot; corresponds to &quot;no pain&quot; and &quot;10&quot; indicates &quot;worst pain imaginable&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Score of Short Form 36-Physical Functioning (SF36-PF) From Screening to 6 Month Follow up Visit</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Short Form 36-PF - score range = 0 - 100. &quot;0&quot; corresponds to &quot;greatest disability&quot; and &quot;100&quot; indicates &quot;no disability&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Score of EuroQuol 5d Visual Analog Scale (EQ-5d VAS) Between Screening and 6 Month Follow up Visit</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>EQ-5d VAS - score range = 0 - 100. &quot;0&quot; corresponds to the &quot;worst imaginable health state&quot; and &quot;100&quot; indicates the &quot;best imaginable health state&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Score of Beck's Depression Inventory (BDI) Between Screening and 6 Month Follow up Visit</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>BDI - score range = 0 - 63. &quot;0&quot; corresponds to &quot;minimal depression&quot; and &quot;63&quot; indicates &quot;severe depression&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Score of Patient Global Impression of Change (PGIC) Between Screening and 6 Month Follow up Visit</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>PGIC - score range = 1 - 7. &quot;1&quot; corresponds to &quot;very much improved&quot; and &quot;7&quot; indicates &quot;very much worse&quot; pertaining to overall activity, symptoms, emotions, and quality of life. The means of these scores and their respective standard deviations are reported for each study group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Score of Oswestry Disability Index (ODI) Between Screening and 6 Month Follow up Visit</measure>
    <time_frame>Baseline and 6 Months</time_frame>
    <description>ODI - score range = 0 - 100. &quot;0&quot; corresponds to &quot;no disability&quot; and &quot;100&quot; indicates the &quot;maximum disability possible&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Back Pain</condition>
  <arm_group>
    <arm_group_label>TransDiscal System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kimberly-Clark TransDiscal System in addition to standard medical management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Management</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard medical management</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TransDiscal System</intervention_name>
    <description>Surgical Procedure using the TransDiscal System to perform disc biacuplasty.</description>
    <arm_group_label>TransDiscal System</arm_group_label>
    <other_name>TransDiscal,disc biacuplasty,disc,ablation,low back pain</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Management</intervention_name>
    <description>Standard medical management, physical therapy, and lifestyle changes.</description>
    <arm_group_label>Medical Management</arm_group_label>
    <other_name>physical therapy, medications,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥21 years

          -  Able to understand the informed consent and able to complete outcome measures

          -  Objective measurements indicating functional impairment related to low back pain

          -  Stabilized on pain medication regimen for &gt;2 months as defined by a &lt;10% change in
             dosage

          -  History of chronic low back pain (&gt;6 months) unresponsive to non-operative care
             (including physical therapy, anti-inflammatory medication, epidurals, diagnostic facet
             joint/medial branch blocks, and sacroiliac joint interventions as performed or deemed
             appropriate by the Investigator)

          -  Score ≥5 on the Visual Analog Scale (VAS) relating specifically to the average daily
             low back pain

          -  Back pain more prominent than leg pain which is commonly exacerbated by flexion or
             bending or prolonged sitting.

          -  Single level concordant pain reproduction present on lumbar discography in desiccated
             disc. Magnetic resonance Imaging (MRI) image also supports discography findings.
             Changes in other disc spaces in the lumbar region do not demonstrate neural
             compressive lesion.

          -  Disc height at least 50% of adjacent control disc

        Exclusion Criteria:

          -  Evidence of compressive radiculopathy with predominant leg pain

          -  Evidence of nucleus pulposus herniation or free disc fragments on MRI

          -  Evidence of &gt; 2 discs dessicated based on MRI or symptomatic involvement of more than
             one lumbar disc levels.

          -  Asymptomatic disc bulges &gt; 5 mm at the treatment level.

          -  Prior lumbar surgery of any kind at the treatment level (micro-discectomies, and/or
             minimally invasive procedures at other levels that are not excluded)

          -  Prior spinal fusion below the T10 Level

          -  Symptoms or signs of lumbar canal stenosis at any level

          -  Evidence of structural abnormality at the lumbar level (except non-symptomatic
             spondylolysis resulting in spondylolithesis no more than Grade 1 upon flexion and
             extension)

          -  Any generalized pain or multifocal pain,conversion or multiple non-anatomical
             complaints

          -  Pending or active compensation claim, litigation or disability income remuneration
             (secondary gain)

          -  Chronic pain associated with significant psychosocial dysfunction

          -  Beck's Depression Index (BDI) score &gt;20

          -  Current pregnancy, recent delivery (within 3 months of consent) or the intent of
             becoming pregnant during the study period.

          -  Systemic or localized infection at the anticipated needle entry site (subject may be
             considered for inclusion once infection is resolved)

          -  Discitis

          -  Allergies to any medication to be used in the procedure

          -  Present symptomatic lumbar spinal fracture

          -  History of uncontrolled coagulopathy, ongoing coagulation treatment or unexplained or
             uncontrollable bleeding that is uncorrectable

          -  Progressive neurological deficits

          -  Within the preceding 2 years, subject has suffered from active narcotic addiction,
             substance abuse or alcohol abuse

          -  Current prescribed opioid medications equivalent to &gt;120 mg of morphine per 24 hours

          -  Uncontrolled immunosuppression (e.g. Acquired Immune Deficiency Syndrome [AIDS],
             cancer, diabetes, etc.)

          -  Body Mass Index (BMI) &gt;32.5 kg/m^2

          -  Participating in another clinical trial/investigation 30 days prior to signing
             informed consent

          -  Negative or indeterminate lumbar discography results as assessed per International
             Spine Intervention Society (ISIS) guidelines

          -  Subject unwilling or unable to comply with follow up schedule or protocol
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Curd, MS</last_name>
    <role>Study Director</role>
    <affiliation>Halyard Health, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University Hospital</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Pain Center</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Orthopedics &amp; Sports Therapy</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PainCare</name>
      <address>
        <city>Linwood</city>
        <state>New Jersey</state>
        <zip>08221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JPS Orthopedic &amp; Sports Medicine</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pain Relief, University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2010</study_first_posted>
  <results_first_submitted>January 13, 2016</results_first_submitted>
  <results_first_submitted_qc>February 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2016</results_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Back Pain</keyword>
  <keyword>Low Back Pain</keyword>
  <keyword>Discogenic Back Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In this study, 67 subjects were randomized, with 63/67 being treated. Three of the non-treated subjects had exclusion criteria violations, while the fourth subject was not treated for an undisclosed reason. The disposition of subjects in the Participant Flow summary is with respect to the primary outcome.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TransDiscal System</title>
          <description>Kimberly-Clark TransDiscal System in addition to standard medical management
TransDiscal System: Surgical Procedure using the TransDiscal System to perform disc biacuplasty.</description>
        </group>
        <group group_id="P2">
          <title>Medical Management</title>
          <description>Standard medical management
Medical Management: Standard medical management, physical therapy, and lifestyle changes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Qualification Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TransDiscal System</title>
          <description>Kimberly-Clark TransDiscal System in addition to standard medical management
TransDiscal System: Surgical Procedure using the TransDiscal System to perform disc biacuplasty.</description>
        </group>
        <group group_id="B2">
          <title>Medical Management</title>
          <description>Standard medical management
Medical Management: Standard medical management, physical therapy, and lifestyle changes.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="11"/>
                    <measurement group_id="B2" value="43" spread="11"/>
                    <measurement group_id="B3" value="42" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Average Daily Pain Visual Analog Scale (VAS) Score Between Screening and Follow up.</title>
        <description>Visual Analog Scale (NRS) - score range = 0 - 10. &quot;0&quot; corresponds to &quot;no pain&quot; and &quot;10&quot; indicates &quot;worst pain imaginable&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Five subjects in the TransDiscal System study arm, and six subjects in the Medical Management study arm did not provide follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>TransDiscal System</title>
            <description>Kimberly-Clark TransDiscal System in addition to standard medical management</description>
          </group>
          <group group_id="O2">
            <title>Medical Management</title>
            <description>Standard Medical Management</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Daily Pain Visual Analog Scale (VAS) Score Between Screening and Follow up.</title>
          <description>Visual Analog Scale (NRS) - score range = 0 - 10. &quot;0&quot; corresponds to &quot;no pain&quot; and &quot;10&quot; indicates &quot;worst pain imaginable&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
          <population>Five subjects in the TransDiscal System study arm, and six subjects in the Medical Management study arm did not provide follow-up data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="2.8"/>
                    <measurement group_id="O2" value="-0.56" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Study Group Subjects With Greater Than 2 Points Decrease or 30% Drop in Average Daily Pain Related Visual Analog Scale (VAS) Score.</title>
        <description>Visual Analog Scale (NRS) - score range = 0 - 10. &quot;0&quot; corresponds to &quot;no pain&quot; and &quot;10&quot; indicates &quot;worst pain imaginable&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TransDiscal System</title>
            <description>Kimberly-Clark TransDiscal System in addition to standard medical management</description>
          </group>
          <group group_id="O2">
            <title>Medical Management</title>
            <description>Standard Medical Management</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Study Group Subjects With Greater Than 2 Points Decrease or 30% Drop in Average Daily Pain Related Visual Analog Scale (VAS) Score.</title>
          <description>Visual Analog Scale (NRS) - score range = 0 - 10. &quot;0&quot; corresponds to &quot;no pain&quot; and &quot;10&quot; indicates &quot;worst pain imaginable&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
          <units>percentage of study group</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Score of Short Form 36-Physical Functioning (SF36-PF) From Screening to 6 Month Follow up Visit</title>
        <description>Short Form 36-PF - score range = 0 - 100. &quot;0&quot; corresponds to &quot;greatest disability&quot; and &quot;100&quot; indicates &quot;no disability&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Five subjects in the TransDiscal System study arm, and seven subjects in the Medical Management study arm did not provide follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>TransDiscal System</title>
            <description>Kimberly-Clark TransDiscal System in addition to standard medical management</description>
          </group>
          <group group_id="O2">
            <title>Medical Management</title>
            <description>Standard Medical Management</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Score of Short Form 36-Physical Functioning (SF36-PF) From Screening to 6 Month Follow up Visit</title>
          <description>Short Form 36-PF - score range = 0 - 100. &quot;0&quot; corresponds to &quot;greatest disability&quot; and &quot;100&quot; indicates &quot;no disability&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
          <population>Five subjects in the TransDiscal System study arm, and seven subjects in the Medical Management study arm did not provide follow-up data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="23"/>
                    <measurement group_id="O2" value="1.7" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Score of EuroQuol 5d Visual Analog Scale (EQ-5d VAS) Between Screening and 6 Month Follow up Visit</title>
        <description>EQ-5d VAS - score range = 0 - 100. &quot;0&quot; corresponds to the &quot;worst imaginable health state&quot; and &quot;100&quot; indicates the &quot;best imaginable health state&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Five subjects in the TransDiscal System study arm, and seven subjects in the Medical Management study arm did not provide follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>TransDiscal System</title>
            <description>Kimberly-Clark TransDiscal System in addition to standard medical management</description>
          </group>
          <group group_id="O2">
            <title>Medical Management</title>
            <description>Standard Medical Management</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Score of EuroQuol 5d Visual Analog Scale (EQ-5d VAS) Between Screening and 6 Month Follow up Visit</title>
          <description>EQ-5d VAS - score range = 0 - 100. &quot;0&quot; corresponds to the &quot;worst imaginable health state&quot; and &quot;100&quot; indicates the &quot;best imaginable health state&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
          <population>Five subjects in the TransDiscal System study arm, and seven subjects in the Medical Management study arm did not provide follow-up data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="42"/>
                    <measurement group_id="O2" value="6" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Score of Beck's Depression Inventory (BDI) Between Screening and 6 Month Follow up Visit</title>
        <description>BDI - score range = 0 - 63. &quot;0&quot; corresponds to &quot;minimal depression&quot; and &quot;63&quot; indicates &quot;severe depression&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Five subjects in the TransDiscal System study arm, and eight subjects in the Medical Management study arm did not provide follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>TransDiscal System</title>
            <description>Kimberly-Clark TransDiscal System in addition to standard medical management</description>
          </group>
          <group group_id="O2">
            <title>Medical Management</title>
            <description>Standard Medical Management</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Score of Beck's Depression Inventory (BDI) Between Screening and 6 Month Follow up Visit</title>
          <description>BDI - score range = 0 - 63. &quot;0&quot; corresponds to &quot;minimal depression&quot; and &quot;63&quot; indicates &quot;severe depression&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
          <population>Five subjects in the TransDiscal System study arm, and eight subjects in the Medical Management study arm did not provide follow-up data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="8"/>
                    <measurement group_id="O2" value="-0.23" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Score of Patient Global Impression of Change (PGIC) Between Screening and 6 Month Follow up Visit</title>
        <description>PGIC - score range = 1 - 7. &quot;1&quot; corresponds to &quot;very much improved&quot; and &quot;7&quot; indicates &quot;very much worse&quot; pertaining to overall activity, symptoms, emotions, and quality of life. The means of these scores and their respective standard deviations are reported for each study group.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Six subjects in the TransDiscal System study arm, and seven subjects in the Medical Management study arm did not provide follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>TransDiscal System</title>
            <description>Kimberly-Clark TransDiscal System in addition to standard medical management</description>
          </group>
          <group group_id="O2">
            <title>Medical Management</title>
            <description>Standard Medical Management</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Score of Patient Global Impression of Change (PGIC) Between Screening and 6 Month Follow up Visit</title>
          <description>PGIC - score range = 1 - 7. &quot;1&quot; corresponds to &quot;very much improved&quot; and &quot;7&quot; indicates &quot;very much worse&quot; pertaining to overall activity, symptoms, emotions, and quality of life. The means of these scores and their respective standard deviations are reported for each study group.</description>
          <population>Six subjects in the TransDiscal System study arm, and seven subjects in the Medical Management study arm did not provide follow-up data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.6"/>
                    <measurement group_id="O2" value="0.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Score of Oswestry Disability Index (ODI) Between Screening and 6 Month Follow up Visit</title>
        <description>ODI - score range = 0 - 100. &quot;0&quot; corresponds to &quot;no disability&quot; and &quot;100&quot; indicates the &quot;maximum disability possible&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
        <time_frame>Baseline and 6 Months</time_frame>
        <population>Five subjects in the TransDiscal System study arm, and seven subjects in the Medical Management study arm did not provide follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>TransDiscal System</title>
            <description>Kimberly-Clark TransDiscal System in addition to standard medical management</description>
          </group>
          <group group_id="O2">
            <title>Medical Management</title>
            <description>Standard Medical Management</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Score of Oswestry Disability Index (ODI) Between Screening and 6 Month Follow up Visit</title>
          <description>ODI - score range = 0 - 100. &quot;0&quot; corresponds to &quot;no disability&quot; and &quot;100&quot; indicates the &quot;maximum disability possible&quot;. The means of these scores and their respective standard deviations are reported for each study group.</description>
          <population>Five subjects in the TransDiscal System study arm, and seven subjects in the Medical Management study arm did not provide follow-up data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="17"/>
                    <measurement group_id="O2" value="0.22" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TransDiscal System</title>
          <description>Kimberly-Clark TransDiscal System in addition to standard medical management
TransDiscal System: Surgical Procedure using the TransDiscal System to perform disc biacuplasty.</description>
        </group>
        <group group_id="E2">
          <title>Medical Management</title>
          <description>Standard medical management
Medical Management: Standard medical management, physical therapy, and lifestyle changes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>iliac artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>sacroiliitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>intervertebral disc displacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>plantar fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>bunion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>parathesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>loss of bladder sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Lavigne</name_or_title>
      <organization>Halyard Health, Inc.</organization>
      <phone>508-837-1427</phone>
      <email>mark.lavigne@hyh.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

